Previous 10 | Next 10 |
2023-11-15 13:44:49 ET Summary Arcellx's CART-ddBCMA reported strong and competitive data in late-line multiple myeloma patients, positioning it well against CAR-T leader Carvykti. The updated data at ASH show that the efficacy held up and even slightly improved compared to the pr...
2023-11-13 11:23:34 ET More on Legend Biotech, Novartis, etc. Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028 New And Improved Novartis Novartis AG (NVS) Q3 2023 Earnings Call Transcript FDA approves Novartis drug Cosentyx for hidr...
The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies targeting Delta-like ligand protein 3 (DLL3), using the Novartis next-generation T-Charge™ CAR-T cell therapy platform Legend Bi...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00am Eastern Time on Monday, November 20, 2023, to review thi...
2023-11-04 10:00:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Opportunity Fund fell 5.03% in Q3, slightly underperforming the broader market. ...
Two oral presentations and five poster presentations at ASH Annual Meeting exhibit new and updated data in the clinical development program for ciltacabtagene autoleucel (cilta-cel) Patient-reported outcomes (PROs) from the CARTITUDE-4 study of cilta-cel versus standard of care in patient...
2023-10-19 01:20:00 ET Summary Baron Health Care Fund invests in companies engaged in the research, development, production, sale, delivery, or distribution of products and services related to the health care industry. The Fund trailed the Benchmark by 217 basis points this quarte...
2023-10-17 07:11:38 ET More on Johnson & Johnson Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy Johnson & Johnson Q3 Earnings Preview: Don't Count On Different Proposition Post Kenvue Spin-Out Johnson & Johnson: The Bull Case Can...
2023-08-21 20:10:21 ET Summary Legend Biotech's Carvykti has shown improved uptake in the second quarter. The company aims to reach an annualized capacity of 10,000 doses of Carvykti by the end of 2025. Reaching the late 2025 goal would translate to quarterly net sales of near...
2023-08-15 14:03:04 ET Legend Biotech Corporation (LEGN) Q2 2023 Earnings Conference Call August 15, 2023, 8:00 AM ET Company Participants Jessie Yeung - Head of Investor Relations and Public Relations Ying Huang - Chief Executive Officer Lori Macomber - Chief Fi...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...